Related Experiment Video
Updated: Jan 7, 2026
High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
Published on: August 16, 2019
Long-term remission of type B insulin resistance syndrome with immunotherapy: A case report
Erika Egawa1, Rei Karasawa1, Yuka Kageyama1
1Division of Diabetes and Endocrinology, Japanese Red Cross Medical Center, Tokyo, Japan.
We report long-term remission in a patient with type B insulin resistance achieved with a combination of immunotherapies. A 55-year-old Japanese man presented with nocturnal hypoglycemia and cytopenia. He also had postprandial hyperglycemia due to severe insulin resistance, which was difficult to manage using high-dose insulin and recombinant human insulin-like growth factor-1. Serological testing showed type B insulin resistance syndrome associated with systemic lupus erythematosus. Glucocorticoids and mycophenolate/azathioprine combination therapy were introduced, resulting in a prompt improvement in glycemic control. The patient has remained in clinical and serological remission for 8 years. Over the past year, he achieved euglycemia with azathioprine monotherapy, without the need for insulin or oral antiglycemic agents.
We report long-term remission in a patient with type B insulin resistance achieved with a combination of immunotherapies. A 55-year-old Japanese man presented with nocturnal hypoglycemia and cytopenia. He also had postprandial hyperglycemia due to severe insulin resistance, which was difficult to manage using high-dose insulin and recombinant human insulin-like growth factor-1. Serological testing showed type B insulin resistance syndrome associated with systemic lupus erythematosus. Glucocorticoids and mycophenolate/azathioprine combination therapy were introduced, resulting in a prompt improvement in glycemic control. The patient has remained in clinical and serological remission for 8 years. Over the past year, he achieved euglycemia with azathioprine monotherapy, without the need for insulin or oral antiglycemic agents.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:22Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...